0000000000249331

AUTHOR

Enrico Breda

showing 4 related works from this author

Breakthrough pain in oncology: A longitudinal study

2010

Abstract Context Existing studies on breakthrough pain (BP) have reported different prevalence rates because of different settings, populations, and assessment methods. These studies have used cross-sectional designs, and the relationship of BP with analgesic treatment has not been evaluated. Objectives The aim of this study was to longitudinally assess BP in cancer patients admitted to oncology units. Methods A consecutive sample of patients admitted to oncology centers was selected. At admission (T0), three months after admission (T3), and six months after admission (T6), data on background pain and BP were recorded. BP was assessed in terms of its intensity, duration, number of episodes,…

Oncologybreakthrough pain; Cancer pain; epidemiology; oncology; Acute Disease; Aged; Analgesics; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasms; Pain; Severity of Illness Index; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)Malemedicine.medical_specialtyLongitudinal studyBreakthrough PainAnalgesicPrevalencePainContext (language use)Severity of Illness Indexlongitudinal study; breakthrough pain; cancer patientsInternal medicineNeoplasmsEpidemiologymedicineHumansLongitudinal StudiesStage (cooking)Cancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedAnalgesicsbusiness.industrylongitudinal studyMiddle Agedbreakthrough painTreatment OutcomeAnesthesiology and Pain MedicineoncologyAcute DiseaseepidemiologyFemaleNeurology (clinical)cancer patientsbusinessCancer pain
researchProduct

Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer. Preliminary activity results of the MITO-2 phase III trial

2008

<i>Background:</i> Based on the efficacy of pegylated liposomal doxorubicin (PLD) in relapsed ovarian cancer, we are conducting a phase III study comparing carboplatin plus either paclitaxel or PLD as first-line therapy in advanced ovarian cancer. Because of limited phase I and II data on PLD plus carboplatin in this setting, we conducted an interim activity analysis. <i>Patients and Methods:</i> Patients with stage 1c-IV epithelial ovarian cancer were randomized to carboplatin AUC 5 plus either paclitaxel 175 mg/m<sup>2</sup> or PLD 30 mg/m<sup>2</sup> every 3 weeks for 6 cycles. The interim activity analysis was planned according to a single…

Oncologyarea under curveCancer Researchendocrine system diseasesmedicine.medical_treatmentneoplasmspolyethylene glycolsantibioticsPegylated Liposomal Doxorubicinsurvival analysischemistry.chemical_compoundpaclitaxelmiddle agedantineoplastic agentsNeoplasms Glandular and EpithelialhumansanthracyclinesAntibiotics AntineoplasticadultGeneral Medicineovarian neoplasmsfemale genital diseases and pregnancy complicationsagedovarian cancerfemaleOncologyPaclitaxelcarboplatinlipids (amino acids peptides and proteins)Anthracyclinesmedicine.drugmedicine.medical_specialtyantineoplasticantineoplastic combined chemotherapy protocolsglandular and epithelialdoxorubicinpegylated liposomal doxorubicinInternal medicineanthracyclines; carboplatin; ovarian cancer; paclitaxel; pegylated liposomal doxorubicin; adult; aged; antibiotics antineoplastic; antineoplastic agents; antineoplastic combined chemotherapy protocols; area under curve; carboplatin; doxorubicin; female; humans; middle aged; neoplasm staging; neoplasms glandular and epithelial; ovarian neoplasms; paclitaxel; polyethylene glycols; survival analysis; treatment outcomemedicineDoxorubicinneoplasm stagingAdvanced ovarian cancerChemotherapybusiness.industryCancermedicine.diseaseCarboplatinEndocrinologychemistrytreatment outcomebusinessOvarian cancer
researchProduct

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MIT…

2011

Purpose Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy. Patients and Methods Chemotherapy-naive patients with stage IC to IV ovarian cancer (age ≤ 75 years; Eastern Cooperative Oncology Group performance status ≤ 2) were randomly assigned to carboplatin area under the curve (AUC) 5 plus paclitaxel 175 mg/m2 or to carboplatin AUC 5 plus PLD 30 mg/m2, every 3 weeks for six cycles. Primary end point was progression-free survival (…

OncologyAdultCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsPolyethylene GlycolDisease-Free Survivallaw.inventionCarboplatinPolyethylene GlycolsAntineoplastic Agentchemistry.chemical_compoundRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansDoxorubicinAgedOvarian NeoplasmsChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryOvarian NeoplasmArea under the curveCancerMiddle Agedmedicine.diseaseCarboplatinSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAOncologychemistryPaclitaxelDoxorubicinQuality of LifeFemalebusinessOvarian cancerHumanmedicine.drug
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct